1. Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis;Sun;Sci. Rep.,2020
2. Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs;Haslam;JAMA Netw. Open,2020
3. Tumor mutational burden and response rate to PD-1 inhibition;Yarchoan;N. Engl. J. Med.,2017
4. Cold tumors: a therapeutic challenge for immunotherapy;Bonaventura;Front. Immunol.,2019
5. Immunomodulation of the tumor microenvironment: turn foe into friend;Locy;Front. Immunol.,2018